Search

314 results for "lecanemab".

Research summaries 285

Showing the best 200 of 285, 171–180, page 18 of 20. Filter these by subject, year and score in the research library →

1. Comparison of the efficacy of updated drugs for the treatment on the improvement of cognitive function in patients with Alzheimer 's disease: A systematic review and network meta- analysisResearch summary

   Research summaries · alzhub.org/study/comparison-of-the-efficacy-of-updated-drugs-for-the-treatment-on-the-39550061

   … 95 % CI -5.08, 0.35), Lecanemab (MD -2.00, 95 % CI -5.25, 1.26), Donanemab (MD -1.45, 95 % CI -4.70, 1.81), Masupirdine (MD -0.83, 95 % CI -3.49, 1.84) were more effective than placebo in improving ADAS-cog. In terms of CDR-SB, …

2. Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiersResearch summary

   Research summaries · alzhub.org/study/current-advances-and-unmet-needs-in-alzheimer-s-disease-trials-for-40528298

   … anti-amyloid therapies such as lecanemab and donanemab, have shown efficacy in slowing progression. However, individuals with DS were excluded from these trials, leaving critical gaps in safety and efficacy data. This perspective …

3. FDA Converts Novel Alzheimer's Disease Treatment to Traditional ApprovalResearch summary

   Research summaries · alzhub.org/study/fda-converts-novel-alzheimer-s-disease-treatment-to-traditional-826d45e8

   The FDA converted lecanemab (Leqembi) from accelerated to full traditional approval after the Phase 3 Clarity AD trial (1,795 patients) confirmed it slowed cognitive decline, making it the first amyloid-targeting antibody to …

4. From Bench to Bedside: Cutting-Edge and Emerging Therapies for Alzheimer's DiseaseResearch summary

   Research summaries · alzhub.org/study/from-bench-to-bedside-cutting-edge-and-emerging-therapies-for-40993929

   … monoclonal antibodies like lecanemab and donanemab (early stage), show promise in slowing cognitive decline by targeting amyloid-beta pathology, their use is associated with risks such as amyloid-related imaging abnormalities …

5. Model of the Impact of Pharmacological and Non-pharmacological Treatment of Alzheimer’s DiseaseResearch summary

   Research summaries · alzhub.org/study/model-of-the-impact-of-pharmacological-and-non-pharmacological-f695fc6b

   … acetilcolinesterasa, y el lecanemab, un anticuerpo que afecta el EA, así como tratamientos no farmacológicos, como la fisioterapia, durante la progresión del Alzheimer. La combinación de tratamientos mostró un efecto beneficioso, …

6. National Coverage Determination: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (NCD 200.3)Research summary

   Research summaries · alzhub.org/study/national-coverage-determination-monoclonal-antibodies-directed-ff44148a

   … antibodies (such as lecanemab and donanemab) for Medicare patients with a documented diagnosis of mild cognitive impairment or mild Alzheimer's dementia and confirmed amyloid pathology, under a framework called 'Coverage with …

7. PET-guided Assessment of Amyloid Clearance and Outcomes in a Real-World Cohort of Patients with Alzheimer Disease undergoing Anti-Amyloid TherapyResearch summary

   Research summaries · alzhub.org/study/pet-guided-assessment-of-amyloid-clearance-and-outcomes-in-a-real-42055956

   Thirty-two patients met inclusion criteria (lecanemab, N=15; donanemab, N=17). Significant Aβ reduction was observed across the cohort (median ΔCL 59.11; p < 0.001) as well as within each treatment group. Most patients meeting …

8. Passive Alzheimer's immunotherapy: A promising or uncertain option?Research summary

   Research summaries · alzhub.org/study/passive-alzheimer-s-immunotherapy-a-promising-or-uncertain-option-37414156

   … (AD), aducanumab and lecanemab, has caused substantial debate. To inform this debate, we reviewed the literature on randomized clinical trials conducted with eight such antibodies focusing on clinical efficacy, cerebral amyloid …

9. Passive anti-amyloid β immunotherapy in Alzheimer's disease-opportunities and challengesResearch summary

   Research summaries · alzhub.org/study/passive-anti-amyloid-immunotherapy-in-alzheimer-s-disease-39549715

   … results of aducanumab, lecanemab, and donanemab. We also review appropriate use recommendations of these novel treatments on patient selection and safety monitoring. Furthermore, estimations of numbers of patient who will qualify …

10. REDEFINING ALZHEIMER’S DISEASE THROUGH MODERN BIOTECHNOLOGY; FROM MOLECULAR PATHOGENESIS TO INNOVATIVE THERAPEUTICS AND DIAGNOSTIC FRONTIERSResearch summary

    Research summaries · alzhub.org/study/redefining-alzheimers-disease-through-modern-biotechnology-from-92541794

    … innovative treatments like lecanemab. It highlights global impact, behavioral aspects, and the role of lifestyle and technology in improving outcomes. Genetic and molecular mutations lead to onset of AD. Mutations in APP, PSEN1, …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

28781 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-06. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.